Search results for "vaccines"

showing 10 items of 554 documents

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

2010

Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the over…

Malemedicine.medical_specialtyMeasles-Mumps-Rubella VaccineInfluenza vaccineAntibodies ViralVaccines AttenuatedRubellaMeaslesDrug IncompatibilityPlacebosRubella vaccineInternal medicineInfluenza HumanmedicineLive attenuated influenza vaccineHumansVaccines CombinedMumpsAdministration IntranasalRubellaGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessMeasles-Mumps-Rubella Vaccinemedicine.drugMeaslesVaccine
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

Serologic control against hepatitis B virus among dental students of the University of Granada, Spain

2015

Background: To evaluate the immunological situation against hepatitis B virus (HBV) of a cohort of dentistry students, to analyze the behavior of the levels of hepatitis B surface antigen (anti-HBs) after the administration of one or three vaccine doses, and to determine the influence of age and sex on the immune response. Material and Methods: This retrospective cohort study included students attending the School of Dentistry of the institution where the study was performed from 2005 to 2012 who had completed the public health vaccination calendar for HBV at the age of 12-13. Data on age, sex, basal anti-HBs levels, post-vaccination anti-HBs results and final anti-HBs levels were collected…

Malemedicine.medical_specialtyUniversitieseducationStudents DentalOdontologíamedicine.disease_causeCohort StudiesYoung AdultInternal medicinemedicineHumansHepatitis B VaccinesYoung adultGeneral DentistryRetrospective StudiesHepatitis B virusOral Medicine and PathologyHepatitis B Surface Antigensbiologybusiness.industryResearchRetrospective cohort studyHepatitis B:CIENCIAS MÉDICAS [UNESCO]Hepatitis Bmedicine.diseaseCiencias de la saludVaccinationOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASImmunologyCohortbiology.proteinFemaleSurgeryAntibodybusinessCohort studyMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Oral HPV Infection: Current Strategies for Prevention and Therapy

2012

Infection with High Risk (HR) Human Papillomaviruses (HPVs) is the main aetiological agent of Cervical Squamous Cell Carcinoma (CSCC) and also associated in a subgroup of other neoplasms, including Oropharyngeal Squamous cell Carcinoma (OPSCC). HPV infection, in genital as in oral mucosa, can also be subclinical or associated with benign proliferative lesions (common warts, condylomas, papillomas) caused mostly by infection with Low Risk (LR)-HPVs. In the last decades, extensive research has resulted in growing knowledge on HPV biology and specifically viral life cycle, biochemical properties of viral proteins and their interaction with the host proteins leading to potential new targets of …

Malemedicine.medical_specialtyUterine Cervical NeoplasmsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryEpidemiologyAnimalsHumansMedicineSex organPapillomavirus VaccinesHealth EducationCommon wartsSubclinical infectionPharmacologyta313business.industryTransmission (medicine)Papillomavirus InfectionsHPV infectionvirus diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsVaccinationOropharyngeal NeoplasmsCervical Squamous Cell CarcinomaHigh Risk (HR)HPV infectionDNA ViralImmunologyCarcinoma Squamous CellEtiologyRNA ViralFemaleMouth DiseasesbusinessCurrent Pharmaceutical Design
researchProduct

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of li…

2006

Abstract Background The incidence of local reactions to diphtheria-, tetanus and acellular pertussis (DTaP-) vaccines in infants and toddlers increases with each subsequent dose, and entire thigh swellings (ETS) have been reported. Lowering the amount of antigen or of adjuvant may decrease the reactogenicity of DTaP while maintaining a protective immune response. Objectives Following priming with three doses of a DTaP vaccine during infancy, the safety, reactogenicity and immunogenicity of nine different candidate DTaP-vaccines with reduced amounts of antigen and/or adjuvant given as fourth (booster) dose were evaluated. Methods Study participants were healthy infants aged 15–27 months at t…

Malemedicine.medical_specialtymedicine.medical_treatmentDose-Response Relationship ImmunologicImmunization SecondaryBooster doseDiphtheria-Tetanus-acellular Pertussis VaccinesAdjuvants ImmunologicDouble-Blind MethodAntigenInternal medicineHumansMedicineAntigens BacterialReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy

2019

Background: Influenza vaccines are updated every year to match the vaccine strains with currently circulating viruses; consequently influenza vaccine effectiveness (IVE) has to be assessed annually.Research design and methods: A test-negative case-control study was conducted within the context of the Italian sentinel influenza surveillance network to estimate IVE by age group, virus subtype, and vaccine brand in medically attended laboratory-confirmed influenza.Results: In Italy, the 2018/19 influenza season was characterized by the co-circulation of influenza A(H1N1)pdm09 and A(H3N2) viruses. The adjusted IVE estimate in preventing influenza was moderate (44.8%, 95% CI: 18.8 to 62.5) again…

Maletest-negative case-control study0301 basic medicinePrevalenceInfluenza vaccine effectiveness test-negative case-control study national influenza surveillance network ItalySettore MED/42 - Igiene Generale E ApplicataInfluenza A Virus H1N1 Subtype0302 clinical medicineDrug DiscoveryEpidemiology030212 general & internal medicineChildInfluenza vaccine effectivenessAged 80 and overnational influenza surveillance networkAge Factorsvirus diseasesMiddle Aged3. Good healthVaccinationTreatment OutcomeItalyInfluenza VaccinesChild PreschoolMolecular MedicineFemaleInfluenza vaccine effectiveness; Italy; national influenza surveillance network; test-negative case-control studyAdultmedicine.medical_specialtyAdolescentInfluenza vaccineImmunologyContext (language use)VirusYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineAnimalsHumansAgedPharmacologybusiness.industryInfluenza A Virus H3N2 SubtypeCase-control studyInfant030104 developmental biologyImmunizationCase-Control StudiesbusinessExpert Review of Vaccines
researchProduct

Effectiveness of an educational intervention on seasonal influenza vaccination campaign adherence among healthcare workers of the Palermo University …

2018

Introduction. Healthcare workers are continuously exposed to the risk of being infected by influenza viruses during their work, thus representing a threat especially for fragile patients. Although the Italian Ministry of Health strongly recommends influenza vaccination for all HCWs, coverage levels in Italy are still far from the expected. Several studies report that one of the preferred strategies to improve vaccination coverage among Healthcare Workers is improving vaccination knowledge through specific multidisciplinary courses. To assess the effectiveness of an educational intervention on influenza vaccination coverage among Healthcare Workers a study was conducted at "Paolo Giaccone" U…

Medical educationMaleRisk perceptionVaccination CoverageImmunization ProgramsHealth PersonnelVaccinationPublic Health Environmental and Occupational HealthInfluenza vaccinationHospitals UniversityInfectious DiseasesItalyInfluenza VaccinesSurveys and QuestionnairesInfluenza HumanHumansFemaleSeasonsAnnali di igiene : medicina preventiva e di comunita
researchProduct

The Dual/Global Value of SARS-CoV-2 Genome Surveillance on Migrants Arriving to Europe via the Mediterranean Routes.

2021

Despite the pandemic, 34,154 migrants, refugees or asylum-seekers landed in Sicily (Italy) in 2020, representing the main point of entry by sea into Europe. The SARS-CoV-2 surveillance program among migrants arriving to Sicily via the Mediterranean Sea, made by the combination of clinical examination and molecular testing, has been integrated by full-genome sequencing strains using the NGS technology from the last week of February. To date, more than one hundred full-genome strains have been sequenced and 8 different lineages have been identified mostly belonging to the lineages B.1.1.7 and B.1.525. As global access to COVID-19 vaccines should be ensured, the need to provide more detailed i…

Mediterranean climatePoint of entryCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RefugeeInfectious and parasitic diseasesRC109-216Genome ViralSettore MED/42 - Igiene Generale E ApplicataGenomeMediterranean seaPandemicHumansSocioeconomicsLetters to the EditorSicilyTransients and MigrantsSARS-CoV-2COVID-19General MedicineGeographyCOVID-19 COVID-19 Vaccines Genome Viral Humans Molecular Diagnostic Techniques SARS-CoV-2Sicily Transients and MigrantsMolecular Diagnostic TechniquesPublic aspects of medicineRA1-1270Annals of global health
researchProduct

Comparative effects of carrier proteins on vaccine-induced immune response

2011

The efficacy of vaccines against major encapsulated bacterial pathogens -Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b (Hib) - has been significantly enhanced by conjugating the respective polysaccharides with different carrier proteins: diphtheria toxoid; non-toxic cross-reactive material of diphtheria toxin(197), tetanus toxoid, N. meningitidis outer membrane protein, and non-typeable H. influenzae-derived protein D. Hib, meningococcal, and pneumococcal conjugate vaccines have shown good safety and immunogenicity profiles regardless of the carrier protein used, although data are conflicting as to which carrier protein is the most immunogenic. Coadmini…

Meningococcal Vaccineschemical and pharmacologic phenomenamedicine.disease_causecomplex mixturesMicrobiologyPneumococcal VaccinesImmune systemAdjuvants ImmunologicConjugate vaccineStreptococcus pneumoniaemedicineHumansHaemophilus VaccinesDiphtheria toxinVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologyChemistryNeisseria meningitidisImmunogenicityPolysaccharides BacterialPublic Health Environmental and Occupational HealthToxoidVaccine efficacyVirologyInfectious DiseasesMolecular MedicineCarrier ProteinsVaccine
researchProduct

Tumor vaccination using messenger RNA: prospects of a future therapy.

2011

While the endeavor to vaccinate against cancer has been pursued for over 20 years, only recently was the first tumor vaccine approved. Among the different antigen formats assessed for vaccination, coding messenger RNA (mRNA) is emerging as a particularly attractive option. It can code for all types of transcript based proteins, is easy and cost efficient to produce, has a favorable safety profile and enables induction of combined immune responses. Within the last few years major developments have been achieved in this field. Clinical approaches use mRNA either for direct administration or for engineering of adoptively transferred dendritic cells. However, there are still challenges to be ov…

Messenger RNAClinical Trials as TopicImmunologyRNACancerDendritic CellsBiologyAdaptive Immunitymedicine.diseaseAcquired immune systemCancer VaccinesVaccinationSafety profileImmune systemAntigenNeoplasmsImmunologymedicineImmunology and AllergyAnimalsHumansRNA MessengerCurrent opinion in immunology
researchProduct